Article info
PDFLetter
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease
- Correspondence to Dr Zachary S Wallace, Rheumatology Unit, Massachusetts General Hospital, Boston, MA 02114, USA; zswallace{at}partners.org
Citation
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease
Publication history
- Received December 27, 2020
- Revised January 5, 2021
- Accepted January 6, 2021
- First published January 12, 2021.
Online issue publication
May 12, 2021
Article Versions
- Previous version (12 January 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage